Jeffrey Kuvin, MD, one of the leading voices behind the push for a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.
Penn Medicine experts conducted two randomized clinical trials, with women receiving text message reminders, bulk orders or letters endorsed by their PCP.
Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.
The device, designed to be worn for up to 24 hours at a time, uses ultrasound technology and artificial intelligence to track how much blood the user's heart is pumping.
Not only does the low-volume contrast protocol preserve supplies, it also protects patients who might be vulnerable to adverse reactions and/or side effects from contrast use.
Jeffrey Kuvin, MD, one of the leading voices behind the push for a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.
Penn Medicine experts conducted two randomized clinical trials, with women receiving text message reminders, bulk orders or letters endorsed by their PCP.